🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Liver cancer is now the fastest rising cause of cancer death in the UK”. HCC is a growing and global health issue that deserves our full attention. WHO expects a further increase in incidence and mortality of >55% by 2040.

TKI-ICI combination as new first line option in aHCC? Another important breakthrough in systemic treatment for aHCC, however in a study population with >85% viral-related HCC. With MASLD set to become the leading risk for HCC, generalisability of these results remains a question.

Only 2⃣ weeks left to register🖋️ Event not to be missed for clinicians and researchers involved in primary #LiverCancer ‼️

🌟 October is #LiverCancerAwarenessMonth, a time to shed light on the various types of liver cancers. 🌟 Liver cancers originate in different liver cells, and understanding them is crucial for early detection and treatment. Knowing these types and their unique characteristics is

An image says more than 180 characters. Very clear message from the @DiLa_lab 💪🎗️ #dagtegenkanker

📢📢 PAPER OUT !! 🤔What biology underlies response to #atezobev in #HCC ? 🔬scRNA and scTCR sequencing of tumour and blood samples 🔜tweetorial of the amazing Sarah Cappuyns 🙏Fruitful collaboration with @DiLa_lab 👀#OpenAccess Paper is here: rdcu.be/dshsE

Leuvense onderzoekers keken met single cell technologie tot op het diepste niveau van de cellen in de tumor en vonden een #biomerker die kan voorspellen of een patiënt met #leverkanker zal reageren op #immuuntherapie of niet. 🔬 Meer weten? 👉bit.ly/41UHxcK

Tissue is the issue, also in #HCC ❗️

Special issue of #COPHAR on GI cancer is finally complete Overview 👉 authors.elsevier.com/a/1iehg5Ea-8VC… 🙏 Angelica Petrillo for editing 🙏 all contributors - Jordan Cloyd, Michele Ghidini MD, PhD, Irene Chong, Rona Yaeger, @FedericaPapacc1, Frederik Peeters and many others!!

Check out our #openaccess review on single-cell omics for liver cancer research including nice figures (by Frederik Peeters) and an overview table of all previous efforts! JHEP Reports

Last weekend, a CCB delegation cycled the #1000km of @komop_tgkanker 🚴🚴 Together with 1250 other teams, they managed to collect almost 7M EUR to support cancer research! Amazing effort, amazing team 🤩 Thank you Bram, Shauni, Isabelle, Lars, Alexandra, Frederik en Amelie!

NIVO + IPI vs LEN (90%) or SORA as 1st line treatment for HCC #ASCO24 🤩Exciting times: More & more options in 1st line HCC 💪Clear improvement in OS with ICI based therapy & sequential therapy 🎯Now, we need biomarkers to guide treatment decisions ESMO - Eur. Oncology @ILCA @EASL

Check out poster 507-TOP @EASL2024. 👉Immune- versus angiogenesis-driven response to #atezobev in #aHCC ⛔️ Resistance related to TREM2+ macros and stromal activation ❗️associated with survival Also, best Poster Award, third year in a row, still can't quite believe it...

Baanbrekende studie TRANSMET toont het aan: patiënten met uitgezaaide dikkedarmkanker naar de lever kunnen geholpen worden met een #levertransplantatie. "Voor jongere kankerpatiënten met een levertumor uit de darm betekent dit de kans op een nieuw leven." bit.ly/3XdKNzF

A deep dive by @FlorianLordick into the #ESOPEC data presented at #ASCO24 - watch the video! 🎥 👇

Clinical and molecular variables associated with early progression to checkpoint inhibitors in MSI-high metastatic colorectal cancer: a retrospective cohort study. clinical-colorectal-cancer.com/article/S1533-…

Original Article Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy Scheiner et al. #LiverX journals.lww.com/hep/abstract/9…

Cell by cell, we shall unravel the contribution of components in patients with #HCC treated with atezo/bev… journal-of-hepatology.eu/article/S0168-…

Five-year OS update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC Journal of Hepatology doi.org/10.1016/j.jhep… 👉OS rate at 5 yrs: 19.6% vs 9.4% 🧐Interesting OS data for pts w/ disease control & any degree of tumour shrinkage ESMO - Eur. Oncology EASL Education ILCA

🔬 our last study on #BTC patients Our findings reveal key clinical and molecular factors linked to maintenance #immunotherapy with #durvalumab in advanced BTC. These insights could guide better patient selection and personalized treatments. onlinelibrary.wiley.com/doi/10.1002/ij…